Mark Simmonds: To ask the Secretary of State for Health whether the National Institute for Health and Clinical Excellence's guidance on supportive and palliative care has been fully implemented in (a) Boston and Skegness, (b) Lincolnshire and (c) England. 
Mr. Ivan Lewis: It is for individual primary care trusts (PCTs), including Lincolnshire Teaching PCT, within the national health service to commission services for their resident population, including end of life care, based on assessments of local needs and priorities. The NHS has been required to set out action plans to achieve compliance with the National Institute for Health and Clinical Excellence recommendations on supportive and palliative care. Implementation is being monitored by strategic health authorities (SHAs).
Mr. Bradshaw: This information is not collected centrally. It is for primary care trusts to commission and determine the clinical design of national health service services based on local health needs.
The term polyclinic can be used to define a range of possible health service models characterised by the co-location and integration of different services, including those traditionally provided in a hospital out-patient setting and diagnostic services. The evidence available from these types of service models is that they can prevent out-patient appointments and reduce hospital admissions. However, their effectiveness will depend on a range of local factors, including the local design of the services in question.
Ann Keen: A pilot public awareness programme on the prostate, set in a primary care trust population, was completed in autumn 2006 and its impact on the local population and the effect it has had on local national health service services has been evaluated. A report based on the results of the pilot and the evaluation, including clear next steps, will be discussed shortly by the Prostate Cancer Advisory Group. The pilot was jointly funded by the Department and signatories to the Prostate Cancer Charter for Action. The Department provided £100,000 towards the pilot.
in 2004 we provided 30,000 to the Men's Health Forum to help fund their publication, the Men and Cancer Manual;
we have provided 135,000 to the Prostate Cancer Charity to increase available information about prostate cancer; and
we are providing 105,000 to the Prostate Cancer Charity to improve awareness of the risks and symptoms of prostate cancer in African and Afro-Caribbean men in Britain.
In addition, the Cancer Reform Strategy set out that we will establish a new National Awareness and Early Diagnosis Initiative. Led by the National Cancer Director, this initiative will bring together the national health service, representatives of local authorities, the Department, the National Cancer Research Institute and the research community, cancer charities and patients to coordinate a programme of activity to support local interventions to increase cancer symptom awareness and encourage earlier presentation.
Information on expenditure on national health service stop smoking services by strategic health authority (SHA) is available in April 2006 to March 2007 and April 2005 to March 2006 from the publications shown as follows. These publications are available in the Library:
Statistics on NHS Stop Smoking Services in England, April 2005 to March 2006 (Annual statistical bulletin) Table 5.7, page 54, which was published on September 28, 2006.
Statistics on NHS Stop Smoking Services in England, April 2006 to March 2007 (Annual statistical bulletin) Table 3.9, page 39, which was published on August 17, 2007.
For earlier years the figures at SHA level have not been published previously. SHA level expenditure on NHS stop smoking services for two years April 2004 to March 2005 and April 2003 to March 2004 are shown in the following table.
|Table 1: Total expenditure( 1) for NHS Stop Smoking Services by Government Office Region and Strategic Health Authority, 2003-04 and 2004-05 , England
|Total expenditure (£000)
|(1) Total expenditure excludes NRT and bupropion (Zyban) on prescription
Lifestyle Statistics. The Information Centre, 2007
Before applying the CE mark the manufacturer must ensure that all risks are removed or minimised and any residual risks are acceptable when weighed against the benefit to the user. The manufacturer must inform users of the residual risks by means of labelling on the device and/or warnings contained in the user information material.
Users, carers, healthcare professionals and others are encouraged to report any safety related problems to Medicines and Healthcare products Regulatory Agency (MHRA) via the MHRA electronic reporting system on their website or by verbal or written contact. This was reinforced in January 2008 with the issue of a new Medical Device Alert aimed specifically at raising the awareness of the need to report incidents involving any type of medical device. MHRA considers all reports received based on the level of risk and carries out investigations accordingly. Where appropriate the MHRA also works with or refers cases to other regulatory bodies in the United Kingdom such as trading standards and also liaises as necessary with other UK Government Departments and Competent Authorities within Europe and also with the United States, Canada, and Australia.
Helen Jones: To ask the Secretary of State for Business, Enterprise and Regulatory Reform what estimate he has made of the cost to business of carers leaving the workforce in each of the last five years. 
Mr. Thomas [holding answer 12 March 2008]: This is a matter for the relevant enforcement authorities; however, the United Kingdom is playing an active part in the current negotiations for new European measures that will, among other provisions, strengthen the protection for CE marking.